| Date Filed | Type | Description |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/30/2023 |
8-K
| Quarterly results |
| 03/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/29/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 03/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/21/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events Interactive Data |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/13/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/13/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 01/10/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 11/28/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 11/15/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 11/02/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/14/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 10/14/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 10/07/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 10/07/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/14/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 09/14/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 09/14/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 09/14/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 09/14/2022 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte...|
Docs:
|
"Business Combination Agreement, by and among Maxpro Capital Acquisition Corp., Apollomics Inc. and Project Max SPAC Merger Sub, Inc",
"Sponsor Support Agreement, by and among Maxpro Capital Acquisition Corp., Apollomics Inc., MP One Investment LLC and the individuals party thereto",
"Company Shareholder Voting Agreement, by and among Maxpro Capital Acquisition Corp., Apollomics Inc. and certain shareholders party thereto",
"Lock-Up Agreement, by Apollomics Inc., MP One Investment LLC and the individuals party thereto",
"Form of Registration Rights Agreement",
"Apollomics Inc., a Late-Stage Clinical Biopharmaceutical Company to be Listed on Nasdaq Through Business Combination with Maxpro Capital Acquisition Corp. - Transaction values Apollomics at pre-money equity value of $899 million - Apollomics is a late-stage clinical biopharmaceutical company developing innovative product candidates for large, unmet medical needs - Broad pipeline of drug candidates across multiple oncology programs; two lead clinical-stage candidates addressing a combined $11 billion non-small cell lung cancer and acute myeloid leukemia market opportunity - Transaction proceeds to accelerate development of late-stage clinical programs, vebreltinib and uproleselan FOSTER CITY, CALIF. and Taipei City, Taiwan – September 14, 2022 – Apollomics Inc. , a late-stage clinical bioph...",
"Investor Presentation, dated September 2022",
"Transcript of Webcast, posted on September 14, 2022",
"Summary Risk Factors" |
|
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 05/16/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 03/31/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 02/14/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/14/2022 |
SC 13G
| Karpus Management, Inc. reports a |
|